JAMA Pre Submission Checklist: What to Verify Before Upload

1. Does this finding change clinical practice in the United States and internationally?

JAMA has a US-centric editorial orientation that is broader than a single specialty but more domestically focused than The Lancet or BMJ. The ideal JAMA paper changes how US physicians manage patients, with clear international applicability. If the finding primarily matters in non-US health systems, The Lancet or BMJ may be a better target.

2. Is the finding clinically meaningful, not just statistically significant?

JAMA editors distinguish between statistical significance and clinical significance. A large trial showing a statistically significant but clinically trivial effect difference will not clear the desk. The magnitude of the effect must be large enough to change actual treatment decisions.

3. Does the abstract open with the clinical question?

JAMA editors and reviewers scan hundreds of abstracts. A structured abstract that opens with the clinical context and states the practice-changing finding in the first two sentences makes a stronger first impression than one that leads with methodology.

4. Is the study design appropriate and adequately powered?

JAMA strongly favors large randomized controlled trials with clinically important primary endpoints. Observational studies are published but face elevated scrutiny. The study must be adequately powered for the primary endpoint with a pre-specified sample size calculation.

5. Will the analysis survive JAMA's statistical review?

JAMA sends manuscripts for independent statistical review, evaluating: sample size and power calculations, pre-specification of the analysis plan, appropriate handling of missing data, multiplicity corrections for secondary endpoints and subgroup analyses, and effect size reporting with confidence intervals. This is one of the most rigorous statistical review processes in medical publishing.

6. Are subgroup analyses identified as pre-specified or exploratory?

JAMA editors and statistical reviewers scrutinize subgroup analyses. Pre-specified subgroups (defined in the protocol) are treated differently from post-hoc explorations. Failing to distinguish these is one of the fastest ways to lose credibility at statistical review.

Before a reviewer ever sees the manuscript, the editor is usually testing three things at speed: whether the clinical question matters to a general medical audience, whether the study design can support the practice claim, and whether the reporting package is clean enough to trust. That is why the checklist should start with the abstract, trial registration, protocol match, and Clinical Perspective before you spend time polishing figure captions.

In Manusights internal analysis of JAMA-targeted clinical manuscripts, the specific failure pattern is not usually "weak science." It is a strong study presented as a specialty finding instead of a general medical decision. If the first screen does not make the clinical action obvious, the paper can feel better matched to JAMA Cardiology, JAMA Oncology, JAMA Neurology, or another network title even when the data are sound.

7. Is the trial registered and does registration match the manuscript?

Prospective registration before enrollment is required. The registration number must appear in the abstract. Protocol amendments must be documented and justified. JAMA checks registration against the manuscript.

8. Are all disclosures complete?

JAMA has detailed financial disclosure requirements. All relationships with industry, consulting fees, equity, patents, and speaker fees must be declared. JAMA also requires AI use disclosure if ChatGPT, Claude, or other AI tools were used in manuscript preparation.

9. Have you considered the JAMA Network transfer?

JAMA has a network of 10+ specialty journals: JAMA Internal Medicine, JAMA Cardiology, JAMA Oncology, JAMA Neurology, JAMA Psychiatry, JAMA Surgery, JAMA Dermatology, JAMA Ophthalmology, JAMA Otolaryngology, and JAMA Pediatrics. Each carries a strong impact factor.

If JAMA desk rejects your paper, they may suggest transfer to the most appropriate network journal. The transfer preserves context and sometimes reviewer reports. This means submitting to JAMA first has a built-in safety net: even if JAMA declines, the work may reach a strong specialty journal faster than if you had targeted it directly.

Before submitting, ask yourself: if JAMA suggests JAMA Cardiology, would that be an acceptable outcome? If yes, submit to JAMA. If the paper only makes sense at the main JAMA journal, be aware that you are competing with a 5 to 7% acceptance rate.

10. Is the manuscript formatted per JAMA's requirements?

JAMA accepts format-free initial submissions for original research, but specific formatting is required at revision. For the initial submission, ensure: continuous line numbering, complete author list with ORCID, structured abstract, Clinical Perspective section (if submitting original research), and conflict of interest disclosures. The Clinical Perspective is JAMA's version of the significance statement: "What Is New?" and "What Are the Clinical Implications?" in bulleted format.

JAMA requires a structured abstract with specific subheadings (Importance, Objective, Design/Setting/Participants, Interventions, Main Outcomes, Results, Conclusions and Relevance). Manuscripts submitted without this format are returned. The "Importance" section is where most abstracts fail: it must state in 1-2 sentences why the clinical question matters to a general physician audience, not to subspecialists. Getting this section right is the single highest-leverage fix for JAMA submissions.

Check your JAMA readiness automatically. The Manusights free scan evaluates your manuscript against JAMA's editorial standards in about 1-2 minutes.

For a paper targeting JAMA, the JAMA submission readiness check provides verified citations from 500M+ live papers, figure-level feedback, and journal-specific calibration. For the most career-defining submissions, Manusights Expert Review connects you with reviewers who have published in and reviewed for JAMA.

• the clinical finding is not practice-changing enough for a general medical journal
• the study is too narrowly specialized (consider a JAMA Network journal directly)
• the effect size is statistically significant but clinically trivial
• the study design has limitations that undermine the clinical claims
• the trial is not registered or registration does not match the manuscript
• the Clinical Perspective box (if applicable) is weak or generic
• financial disclosures are incomplete

For more detail, see JAMA Under Review: Status Meanings.

Worth the investment if:

• You are targeting JAMA where desk rejection is high
• A rejection would cost 3-6 months in resubmission cycles
• The paper is career-critical
• You want an independent assessment before submission

Skip it if:

• You have a strong track record at JAMA and know the editors
• Experienced colleagues have already reviewed the manuscript thoroughly
• Your timeline is too tight to act on the feedback
• The study has fundamental design issues needing new experiments

The most common JAMA miss is not that the paper is weak. It is that the manuscript is actually better matched to a JAMA Network specialty journal and the authors never force that decision early. We usually look first at the structured abstract and the implied reader. If the "Importance" section only makes sense to a subspecialist, or if the clinical implication is real but narrow, the paper may still be strong but the flagship journal is the wrong entry point.

The fastest way to diagnose that problem is to ask whether a general internist would understand the practical takeaway before reaching the Methods section. If not, the manuscript is usually underspecified for JAMA even when the underlying study is solid.